GLP1R and atherosclerosis: In conclusion, it is particularly concerning that relative to cardiovascular evidence-based therapies (GLP-1 RA, SGLT-2i, ACEI/ARB, statins, and aspirin), was associated with a lower risk of the 3-point MACE, HHF and end-stage kidney disease or doubling of serum creatinine level outcome in T2DM patients with ASCVD or high risk of ASCVD after adjusting for covariates.